Seegene launches Global Million Clinical Study
July 10, 2026—Seegene has launched the Global Million Clinical Study, which aims to evaluate the clinical utility and potential impact of syndromic PCR testing using real-world data.
Webinars and Sponsored Roundtables — Register Now
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, July 21, 2026, 11:00-11:30 AM CT
Learning Objectives:
- Explain how transparency and manufacturer partnerships improve quality, consistency, and decision-making confidence in specimen management.
- Evaluate blood collection tubes beyond cost and commodity assumptions, incorporating clinical impact and risk into decision-making.
- Assess the potential risk points when using a blood collection device that has not been cleared for a specific purpose.
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 29, 2026, 1:00-2:00 PM ET
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center-Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center-Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears Visby’s at-home multiviral PCR test
July 9, 2026—The FDA has cleared the Visby Medical Flu and COVID-19 at-home PCR test.
Bio-Rad launches Vericheck ddPCR kits for QX700 platform
July 7, 2026—Bio-Rad Laboratories launched its QX700 system-compatible Vericheck ddPCR kit portfolio for quality control workflows in advanced cell and gene therapy development and other biopharma applications.
Epredia launches SlideMate thermal slide printer
July 6, 2026—Epredia has launched sales of the SlideMate thermal slide printer, engineered to help clinical laboratories protect tissue samples, strengthen sample traceability, and streamline workflow efficiency during cancer diagnosis.
Versant expands collaboration with Leica Biosystems
June 30, 2026—Leica Biosystems and Versant Diagnostics are expanding their collaboration to advance digital pathology adoption.
Roche launches Axelios 1 NGS platform
June 29, 2026—Roche has launched the Axelios 1, a next‑generation single-molecule sequencing platform powered by proprietary sequencing by expansion technology.
Thermo Fisher launches LabLink 360 QA software
June 26, 2026—Thermo Fisher Scientific has launched the Thermo Scientific LabLink 360 Quality Assurance software, designed to help clinical laboratories simplify quality control workflows, accelerate QC review and decision-making, improve visibility into QC performance, and manage QC operations.
Merck to acquire Bio-Techne for $11.3 billion
June 25, 2026—Merck (Darmstadt, Germany) has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corp. for approximately $11.3 billion.
FDA-approved, at-home ColoSense test now available
June 24, 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC.
Liaison Nes group A strep assay gets FDA clearance, CLIA waiver
June 23, 2026—Diasorin has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration for its group A streptococcus assay, for use on the Liaison Nes point-of-care molecular diagnostics platform.